NetworkNewsBreaks – Replimune Group, Inc. (NASDAQ: REPL) Secures $80 Million in Underwritten Public Offering
Replimune Group (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, has closed an underwritten public offering of 3,678,031 shares of its common stock at a public offering price of $13.61 per share. According to the update, Replimune also, in addition, and in lieu of common stock, closed a public offering of pre-funded warrants to purchase 2,200,000 shares of its common stock at a purchase price of $13.6099 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. Replimune…







